Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways.

Journal: Journal of clinical urology
Published Date:

Abstract

INTRODUCTION: Modern image-guided biopsy pathways at diagnostic centres have greatly refined the investigations of men referred with suspected prostate cancer. However, the referral criteria from primary care are still based on historical prostate-specific antigen (PSA) cut-offs and age-referenced thresholds. Here, we tested whether better contemporary pathways and biopsy methods had improved the predictive utility value of PSA referral thresholds.

Authors

  • Artitaya Lophatananon
    Division of Population Health, Health Services Research & Primary Care Centre, University of Manchester, UK.
  • Alexander Light
    Division of Urology, Department of Surgery, University of Cambridge, UK.
  • Nicholas Burns-Cox
    Department of Urology, Somerset NHS Foundation Trust, UK.
  • Angus Maccormick
    Department of Urology, Somerset NHS Foundation Trust, UK.
  • Joseph John
    Department of Urology, Royal Devon and Exeter NHS Foundation Trust and University of Exeter, UK.
  • Vanessa Otti
    Department of Urology, Royal Devon and Exeter NHS Foundation Trust and University of Exeter, UK.
  • John McGrath
    Department of Urology, Royal Devon and Exeter NHS Foundation Trust and University of Exeter, UK.
  • Pete Archer
    Department of Urology, Southend Hospital, UK.
  • Jonathan Anning
    Department of Urology, North Bristol NHS Trust, UK.
  • Stuart McCracken
    Department of Urology, South Tyneside and Sunderland NHS Trust, UK.
  • Toby Page
    Department of Urology, Newcastle Hospitals NHS Trust, UK.
  • Ken Muir
    Division of Population Health, Health Services Research & Primary Care Centre, University of Manchester, UK.
  • Vincent J Gnanapragasam
    Division of Urology, Department of Surgery, University of Cambridge, UK.

Keywords

No keywords available for this article.